Interleukin 6 and Complement Serum Level Study in Parkinson's Disease

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2018 Feb 14

PMID 29435648

Citations 28

Authors

Branislav Vesely

Michal Dufek

Vojtech Thon

Miroslav Brozman

Silvia Kiralova

Tatiana Halaszova

Eva Koritakova

Ivan Rektor

Affiliations

Soon will be listed here.

Abstract

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

Citing Articles

Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.

Zhao Z, Fu Q, Guo X, He H, Yang G Actas Esp Psiquiatr. 2025; 53(1):181-188.

PMID: 39801407 PMC: 11726199. DOI: 10.62641/aep.v53i1.1779.

No causal relationship between ankylosing spondylitis and Parkinson's disease: Insights from Mendelian randomization studies.

Chen J, Xu Q, Wang Y, Jiang S, Zhang B, Tian J Heliyon. 2024; 10(22):e40381.

PMID: 39641025 PMC: 11617765. DOI: 10.1016/j.heliyon.2024.e40381.

Diagnostic value and correlation analysis of serum cytokine levels in patients with multiple system atrophy.

Chen X, Chen S, Lai X, Fu J, Yang J, Ou R Front Cell Neurosci. 2024; 18:1459884.

PMID: 39295596 PMC: 11409425. DOI: 10.3389/fncel.2024.1459884.

Associations Between Neuropsychiatric Symptoms and Inflammation in Neurodegenerative Dementia: A Systematic Review.

Swann P, Mirza-Davies A, OBrien J J Inflamm Res. 2024; 17:6113-6141.

PMID: 39262651 PMC: 11389708. DOI: 10.2147/JIR.S385825.

The complement system in neurodegenerative diseases.

Nimmo J, Byrne R, Daskoulidou N, Watkins L, Carpanini S, Zelek W Clin Sci (Lond). 2024; 138(6):387-412.

PMID: 38505993 PMC: 10958133. DOI: 10.1042/CS20230513.

References

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Kang S, Tanaka T, Kishimoto T . Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2014; 27(1):21-9. DOI: 10.1093/intimm/dxu081. View

Palhagen S, Qi H, Martensson B, Walinder J, Granerus A, Svenningsson P . Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol. 2009; 257(4):524-32. DOI: 10.1007/s00415-009-5353-6. View

Dufek M, Hamanova M, Lokaj J, Goldemund D, Rektorova I, Michalkova Z . Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord. 2008; 15(4):318-20. DOI: 10.1016/j.parkreldis.2008.05.014. View

Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K . Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. Parkinsonism Relat Disord. 2015; 21(10):1219-26. DOI: 10.1016/j.parkreldis.2015.08.024. View

Berczi I, Quintanar-Stephano A, Kovacs K . Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci. 2009; 1153:220-39. DOI: 10.1111/j.1749-6632.2008.03975.x. View

Lindqvist D, Hall S, Surova Y, Nielsen H, Janelidze S, Brundin L . Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013; 33:183-9. DOI: 10.1016/j.bbi.2013.07.007. View

Reyes M, Perez-Lloret S, Lloret S, Gerschcovich E, Gerscovich E, Martin M . Addenbrooke's Cognitive Examination validation in Parkinson's disease. Eur J Neurol. 2008; 16(1):142-7. DOI: 10.1111/j.1468-1331.2008.02384.x. View

10.

Hofmann K, Schumacher Schuh A, Saute J, Townsend R, Fricke D, Leke R . Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res. 2009; 34(8):1401-4. DOI: 10.1007/s11064-009-9921-z. View

11.

Dunn A . Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res. 2007; 6(1-2):52-68. PMC: 2136407. DOI: 10.1016/j.cnr.2006.04.002. View

12.

Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O . Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One. 2012; 7(10):e47387. PMC: 3474801. DOI: 10.1371/journal.pone.0047387. View

13.

Chen H, Zhang S, Hernan M, Schwarzschild M, Willett W, Colditz G . Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003; 60(8):1059-64. DOI: 10.1001/archneur.60.8.1059. View

14.

Olson K, Gendelman H . Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol. 2015; 26:87-95. PMC: 4716884. DOI: 10.1016/j.coph.2015.10.006. View

15.

Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniuk M . Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008; 441(2):158-62. DOI: 10.1016/j.neulet.2008.06.040. View

16.

Umemura A, Oeda T, Yamamoto K, Tomita S, Kohsaka M, Park K . Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease. PLoS One. 2015; 10(8):e0136722. PMC: 4550234. DOI: 10.1371/journal.pone.0136722. View

17.

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T . Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett. 1996; 211(1):13-6. DOI: 10.1016/0304-3940(96)12706-3. View

18.

Williams-Gray C, Wijeyekoon R, Yarnall A, Lawson R, Breen D, Evans J . Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord. 2016; 31(7):995-1003. PMC: 4957620. DOI: 10.1002/mds.26563. View

19.

MAHONEY F, BARTHEL D . FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965; 14:61-5. View

20.

Dantzer R, OConnor J, Freund G, Johnson R, Kelley K . From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2007; 9(1):46-56. PMC: 2919277. DOI: 10.1038/nrn2297. View